Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745661 | 0.95 | F2 (0.50) | F2PRSS1PRSS2PRSS3NSD2 | |
| SCHEMBL3730111 | 0.87 | F2 (0.71) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3740765 | 0.83 | F2 (0.64) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3745909 | 0.82 | F2 (0.37) | F2NSD2 | |
| SCHEMBL3745657 | 0.80 | F2 (0.47) | F2PRSS1PRSS2PRSS3NSD2 | |
| SCHEMBL7110448 | 0.79 | F2 (0.54) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7112024 | 0.78 | F2 (0.73) | F2 | |
| SCHEMBL3735597 | 0.78 | F2 (0.53) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7108067 | 0.76 | F2 (0.54) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3735682 | 0.76 | NSD2 (0.34) | F2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829584-B2 | Pyridines and pyridine N-oxides as modulators of thrombin | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-09 | — | — | US | disclosed |
| US-7829584-B2 | Pyridines and pyridine N-oxides as modulators of thrombin | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-09 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109459-A2 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, NV (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | F2, F11, TBXAS1 | F2 1/4885PRSS1 57/4885PRSS2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.